Core Viewpoint - The recent listing of four new stocks on the Hong Kong Stock Exchange, including Xiaoma Zhixing, has seen mixed results, with Xiaoma Zhixing experiencing a significant drop in share price, raising concerns about its commercialization capabilities and financial health [1][2]. Group 1: Stock Performance - Among the four newly listed stocks, only Wangshan Wangshui-B saw a substantial increase in share price, closing up 145.73% at 82 HKD per share [1]. - Xiaoma Zhixing's share price fell 9.28% from its issue price of 139 HKD, closing at 126.1 HKD, with an intraday drop of 14.53% [1]. - Xiaoma Zhixing's initial public offering (IPO) in the U.S. also faced challenges, with its first-day closing price at 12 USD per share, down 7.69% [1]. Group 2: Financial Performance - Xiaoma Zhixing's total revenue projections for 2022 to 2025 are 0.68 million USD, 0.72 million USD, 0.75 million USD, and 0.35 million USD respectively [1]. - The company reported net losses of 1.48 million USD, 1.25 million USD, and 2.74 million USD for the years 2022 to 2024, with the 2024 loss exceeding total revenue for the previous three and a half years [2]. - In the first half of 2025, Xiaoma Zhixing's net loss increased by 87.24% to 0.96 million USD [2]. Group 3: Research and Development Expenditure - Xiaoma Zhixing's R&D expenses from 2022 to 2024 were 1.54 million USD, 1.23 million USD, and 2.40 million USD, totaling over 5.17 million USD, while total revenue during the same period was only 2.15 million USD [2]. - In the first half of 2025, R&D spending reached 96.5 million USD, accounting for 272.3% of the revenue of 35.43 million USD [2]. Group 4: Cash Flow and Market Sentiment - The company experienced a cash outflow from operating activities of 1.1 million USD in 2024 and 0.8 million USD in the first half of 2025, indicating challenges in cash generation [2]. - Industry experts suggest that Xiaoma Zhixing's continued losses and high R&D costs, coupled with weak revenue growth and tight cash flow, reflect skepticism in the market regarding its ability to convert technological advancements into commercial profitability [2].
小马智行港股挂牌首日再破发 股价下跌超9%